The study is a retrospective cohort study that utilizes medical records from the BiologicTx. Data accrual starts upon initial home infusion nurse visit until the most recent home infusion nurse visit. Infusion related adverse events are quantified as number of patients with adverse event over the total number of patients and number of event over total number of home infusion visits.
Study Type
OBSERVATIONAL
Enrollment
37
Proportion of infusion related serious adverse events in adult kidney-only transplant recipients who are treated with belatacept in home infusion settings
Time frame: 24 hours after the date of a home infusion visit
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.